A Phase 2 interventional study of Pembrolizumab in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer, sponsored by University College, London. Completed at 4 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by University College, London · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing pembrolizumab in Ovarian Neoplasms — 7 open to participants now, 13 under way, 2 of them phase 3. pembrolizumab · Ovarian Neoplasms.
Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, this one is the 30th largest by enrollment, is one of 3 that started in 2019, is one of 26 in phase 2, and was the 16th registered.
3,385 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →7 of the 35 studies testing pembrolizumab in Ovarian Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Obstetrics & Gynecology Hospital of Fudan University · Sites in China
Ages 18–75 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Sheba Medical Center · Sites in Israel
Ages 18+ · Women only
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 30 · Phase 3 3
First in 2010; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 38 across the 35 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 35 have an industry lead sponsor. The 10 most frequent:
University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
University College, London has 9 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing pembrolizumab in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06083844M.D. Anderson Cancer CenterPhase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | 2027-09-30 |
| NCT07261683Obstetrics & Gynecology Hospital of Fudan UniversityPhase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab. The aim of the translational research is to study the immune microenvironment before and during pembrolizumab therapy.
This study aimed to investigate the effect of maintenance pembrolizumab in patients who underwent treatment with weekly paclitaxel for platinum-resistant recurrent ovarian cancer and either responded or progressed after a minimum of 4 cycles of treatment.
Participants were enrolled to receive 3 weekly pembrolizumab until progression. This was a non-randomised phase II study, and the population may be different from those who received paclitaxel and bevacizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Has received prior systemic anti-cancer therapy including agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to registration.
Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maintenance treatment with trial drug pembrolizumab; 200mg IV every 21 days until progression, unacceptable toxicity, patient or clinician decision.
Drug: Pembrolizumab
Intravenous infusion
Also known as: Keytruda
Progression-Free Survival Rate at 6 Months From Start of Study Treatment (Maintenance Pembrolizumab)
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), with at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions or unequivocal progression of existing non-target lesions is also considered progression. Using A'Hern's single-stage phase II design with a one-sided 5% significance level and 80% power, ≥16 participants needed to be alive and progression-free at 6 months for the protocol aim to be reached.
Time frame: 6 months from start of study treatment (maintenance pembrolizumab)
Progression Free Survival at 6 Months Measured From the Start of Pre-trial Weekly Paclitaxel
Progression Free Survival at 6 months was measured from the start of pre-trial weekly paclitaxel using Kaplan-Meier estimates with censoring on the date of last study assessment.
Time frame: 6 months from the start of weekly previously administered standard of care paclitaxel to the date of first progression or death from any cause.
Overall Survival
Kaplan-Meier estimates were used to analyse overall survival from the start of maintenance pembrolizumab to the date of death from any cause.
Time frame: From start of study treatment until the date of death from any cause or end of study whichever came first, assessed up to 50 months.
Disease Response
Disease response as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, using CT scan assessment: Complete Response- disappearance of all target lesions; Partial Response at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Progressive Disease - at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (Note: the appearance of one or more new lesions and unequivocal progression is also considered progression); Stable Disease - neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: Before cycle 1, cycle 4 and cycle 7 of study treatment, then every 12 weekly (4 cycles) during treatment until progression up to 24 months.
Treatment Compliance
The number and percentage of patients who stopped treatment due to any reason other than disease progression were analysed. A median of 3.5 cycles of pembrolizumab were given. Nineteen participants stopped due to disease progression and one participant discontinued due to a treatment related adverse event.
Time frame: Date of first study treatment administration dose until the date of last administration dose of study treatment, assessed for duration of study treatment in all participants: up to 42 months.
Open label, single arm study. Consented and eligible participants were enrolled onto the study to receive study treatment.
| Milestone | Treatment |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), with at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions or unequivocal progression of existing non-target lesions is also considered progression. Using A'Hern's single-stage phase II design with a one-sided 5% significance level and 80% power, ≥16 participants needed to be alive and progression-free at 6 months for the protocol aim to be reached.
| Percentage of participants | Treatment |
|---|---|
| Progression-Free Survival Rate at 6 Months From Start of Study Treatment (Maintenance Pembrolizumab) | 5.0 (0.3 to 20.5) |
Progression Free Survival at 6 months was measured from the start of pre-trial weekly paclitaxel using Kaplan-Meier estimates with censoring on the date of last study assessment.
| Percentage of participants | Treatment |
|---|---|
| Progression Free Survival at 6 Months Measured From the Start of Pre-trial Weekly Paclitaxel | 95.0 (69.5 to 99.3) |
Kaplan-Meier estimates were used to analyse overall survival from the start of maintenance pembrolizumab to the date of death from any cause.
| Months | Treatment |
|---|---|
| Overall Survival | 10.5 (6.2 to 21.1) |
Disease response as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, using CT scan assessment: Complete Response- disappearance of all target lesions; Partial Response at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Progressive Disease - at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (Note: the appearance of one or more new lesions and unequivocal progression is also considered progression); Stable Disease - neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
| Percentage of participants | Treatment |
|---|---|
| Disease Response | 5 (0.1 to 24.9) |
The number and percentage of patients who stopped treatment due to any reason other than disease progression were analysed. A median of 3.5 cycles of pembrolizumab were given. Nineteen participants stopped due to disease progression and one participant discontinued due to a treatment related adverse event.
| Participants | Treatment |
|---|---|
| Treatment Compliance | 1 |
Collected over From consent until 30 calendar days (or 16 weeks for adverse events of special interest and serious adverse events) post last treatment administration, assessed one month before first study dose, every 3 weeks during treatment and at 30 days post last treatment administration, up to 30 months. Any serious adverse reactions were assessed every 12 weeks up until participants' last follow-up, up to 32 months. All-Cause Mortality was from first dose until death, assessed up to 50 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Treated | 18/20 (90%) | 4/20 (20%) | 20/20 (100%) |
| Event | Participants Treated |
|---|---|
| UrticariaSkin and subcutaneous tissue disorders | 1/20 |
| Lung InfectionInfections and infestations | 1/20 |
| Immune-mediated hepatitisHepatobiliary disorders | 1/20 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/20 |
| DiarrhoeaGastrointestinal disorders | 1/20 |
| Chest wall painMusculoskeletal and connective tissue disorders | 1/20 |
| Event | Participants Treated |
|---|---|
| HypertensionVascular disorders | 9/20 |
| VomitingGastrointestinal disorders | 7/20 |
| ConstipationGastrointestinal disorders | 6/20 |
| NauseaGastrointestinal disorders | 6/20 |
| Abdominal painGastrointestinal disorders | 5/20 |
| DiarrhoeaGastrointestinal disorders | 5/20 |
| PainGeneral disorders | 5/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/20 |
| FatigueGeneral disorders | 4/20 |
| Weight lossInvestigations | 4/20 |
Patients with recurrent high-grade serous ovarian cancer who received at least 4 cycles of paclitaxel with stable disease.
| Age, Customized(years) | Treatment |
|---|---|
| Age | 61 (41 to 78) |
| Sex: Female, Male(Participants) | Treatment |
|---|---|
| Female | 20 |
| Male | 0 |
| Race and Ethnicity Not Collected(Participants) | Treatment |
|---|
| Region of Enrollment(Participants) | Treatment |
|---|---|
| United Kingdom | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Dec 2025, 78 months.
Results were first posted in May 2026, 5 months after primary completion.
Of 228 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 78 months is above that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab